<SEC-DOCUMENT>0001144204-16-106086.txt : 20160601
<SEC-HEADER>0001144204-16-106086.hdr.sgml : 20160601
<ACCEPTANCE-DATETIME>20160601071526
ACCESSION NUMBER:		0001144204-16-106086
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160601
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160601
DATE AS OF CHANGE:		20160601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		161687902

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v441437_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CURRENT
REPORT Pursuant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>to
Section 13 or 15(d) of the</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Securities
Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Date of report (Date
of earliest event reported): <U> June 1, 2016</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 100%; font: 10pt Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SANGAMO BIOSCIENCES, INC.</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact Name of Registrant as Specified in Its Charter)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font: 10pt Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction of Incorporation)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>000-30171</b></font></td>
    <TD STYLE="width: 50%; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>68-0359556</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>501 Canal Blvd</b></font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richmond, California 94804</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 100%; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(510) 970-6000</b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&rsquo;s Telephone Number, Including Area Code)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former Name or Former Address, if Changed Since Last Report)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.25in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 0.25in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">o</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">o</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">o</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Wingdings; font-size: 10pt">o</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 1in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 5.02. </b></font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. </b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of June 1, 2016, the board of directors (the &ldquo;Board&rdquo;)
of Sangamo BioSciences, Inc. (the &ldquo;Company&rdquo;) appointed Dr. Alexander (Sandy) Macrae to serve as President and Chief
Executive Officer of the Company. Also effective as of June 1, 2016, Mr. Edward O. Lanphier retired from his position as the Company&rsquo;s
President and Chief Executive Officer. The Board also appointed Mr. Lanphier to serve as the non-executive Chairman of the Board
to be effective immediately following the Company&rsquo;s 2016 Annual Meeting of Stockholders, which is scheduled to be held on
June 14, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Macrae, age 53, served as the Global Medical Officer of
Takeda Pharmaceuticals, a pharmaceutical company, from 2012 to March 2016, where he established and led the global medical office,
which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences
and knowledge and informatics. From 2001 to 2012, Dr. Macrae held various positions at GlaxoSmithKline, a global healthcare company,
including Senior Vice President, Emerging Markets R&amp;D from 2009 to 2012; Vice President, Business Development from 2007 to
2008; Vice President/Global Lead, Clinical Development Musculoskeletal Inflammatory Genitourinary Therapy area from 2004 to 2007;
and Vice President, Anti-Infectives and Diseases of the Developing World from 2001 to 2004. He received his B.Sc. in pharmacology
with first-class honors and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians.
Dr. Macrae received his Ph.D. in molecular genomics from King&rsquo;s College, Cambridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Compensatory Arrangement with Dr. Macrae</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective as of June 1, 2016, the Company entered into an employment
agreement with Dr. Macrae (the &ldquo;Employment Agreement&rdquo;) setting forth the terms and conditions of his employment as
President and Chief Executive Officer.&nbsp; Pursuant to the Employment Agreement, Dr. Macrae will receive a base salary of $600,000
per year.&nbsp; Dr. Macrae is entitled to receive an<FONT STYLE="color: red"> </FONT>annual cash bonus based upon the Company&rsquo;s
achievement of specified objectives under the Company&rsquo;s executive bonus plan with a target bonus of 60% of his base salary,
pro-rated for 2016 based on the period of service.&nbsp; In addition, upon commencement of employment, Dr. Macrae will receive
a sign-on bonus in the amount of $200,000 which will be subject to repayment to the Company should his employment be terminated
by the Company for cause or by him without good reason within one year. In connection with his appointment, the Compensation Committee
granted Dr. Macrae a stock option (the &ldquo;Option&rdquo;) to purchase up to 700,000 shares of common stock of the Company. The
grant date of the Option will be June 3, 2016, and the exercise price of the Option will be the closing price of the Company&rsquo;s
common stock reported on the NASDAQ Global Select Market on the grant date.&nbsp; One-quarter (1/4) of the Option shares will vest
twelve (12) months from June 1, 2016 and the remainder will vest in equal monthly installments for thirty-six (36) months thereafter,
provided that Dr. Macrae remains a full-time employee through each such vesting date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the Company terminates Dr. Macrae&rsquo;s employment without
cause or Dr. Macrae terminates his employment for good reason, in either case within 12&nbsp;months following a change in control
and Dr. Macrae executes a general release of all claims in favor of the Company, Dr. Macrae will receive a severance payment equal
to 1.5 times his annual base salary in effect on his termination date plus his target bonus for the year in which such termination
occurs payable over a 12 month period and reimbursement for continued health care coverage under COBRA for up to twelve months.
In addition, the Option and any other equity awards granted to him will vest on an accelerated basis&nbsp; with respect to (i)
50% of the then unvested shares in the event the change in control occurs within two years following commencement of employment
and (ii) 100% of the then unvested shares in the event the change in control occurs more than two years following commencement
of employment; any outstanding option as so accelerated shall remain exercisable for a period of 12 months following termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the Company terminates Dr. Macrae&rsquo;s employment without
cause or Dr. Macrae terminates his employment for good reason in the absence of a change in control or more than 12&nbsp;months
after a change in control and Dr. Macrae executes a general release of all claims in favor of the Company, Dr. Macrae will receive
salary continuation payments for a twelve month period following his termination date at his rate of base salary in effect on his
termination date and reimbursement for continued health care coverage under COBRA for up to twelve months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Employment Agreement is only
a summary and qualified in its entirety by the text of the Employment Agreement, a copy of which will be filed as an exhibit to
the Company&rsquo;s next Quarterly Report on Form 10-Q.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 1in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d) </b></font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits.</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 1in; font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-decoration: underline"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Exhibit</u></font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; text-decoration: underline"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Description</u></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated June 1, 2016.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD COLSPAN="2" STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SANGAMO BIOSCIENCES, INC.</B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; width: 50%">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; width: 5%">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; width: 45%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ H. Ward Wolff</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: H. Ward Wolff</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line">&nbsp;</td>
    <TD STYLE="font-family: Courier New, Courier, Monospace; layout-grid-mode: line"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Executive Vice President and Chief Financial Officer</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: June 1, 2016</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v441437_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head><META content="text/html; charset=utf-8"></META></head><body style="font-size:10pt;font-family:Arial;color:black;"><div style="width:100%;margin-left:10pt">&nbsp;</DIV>

<DIV STYLE="width: 100%; margin-left: 10pt; text-align: right"><B>Exhibit 99.1</B></DIV>

<DIV STYLE="width: 100%; margin-left: 10pt">&nbsp;</DIV>

<DIV STYLE="width: 100%; margin-left: 10pt"><p style="text-align:center"><b>Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And CEO; Sandy Macrae Named As Successor</b></p>
<br /><br />Leadership Transition Underlines Evolution from a Platform Company to a Therapeutic Product Company
<br /><br />Dr. Macrae Appointed as President and CEO - Mr. Lanphier to Assume Chairmanship of the Board of Directors - Current Chairman William Ringo to Remain on the Board
<br /><br />Company to Host Conference Call and Webcast Today at 8:30 am ET</div><div style="width:100%;margin-left:10pt;"><div style="margin:0;margin-top:16pt;"><p><b>
 </b><i>
 </i>

</p><p>RICHMOND, Calif., June 1, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today announced the company has appointed Alexander &#39;Sandy&#39; Macrae, M.B., Ch.B, Ph.D., MRCP, as president and chief executive officer to succeed current president and CEO, Edward Lanphier. Mr. Lanphier is retiring from the day-to-day leadership of Sangamo. He will continue as a member of the board of directors and, as previously disclosed, will assume the chairmanship of the board immediately following the 2016 annual meeting of stockholders which will be held on June 14, 2016. Mr. William Ringo, Sangamo&#39;s current chairman since 2010, will remain on the board as chairman of the Nominating and Governance Committee and member of the Compensation Committee. Dr. Macrae has assumed the CEO role effective today.</p><div
id="prni_dvprnejpg76faleft" style="TEXT-ALIGN: left; WIDTH: 100%"><img src="sf35903logo.jpg" id="prnejpg76faleft" title="Sangamo BioSciences, Inc." border="0" alt="Sangamo BioSciences, Inc." align="middle"></div><p>Dr. Macrae, a physician scientist with deep experience in clinical development and global business strategy, most recently served as global medical officer of Takeda Pharmaceuticals where he established and led its global medical office. In the 15 years prior, Dr. Macrae held roles of increasing responsibility at Smith Kline Beecham and Glaxo SmithKline (GSK), where his last role was as Senior Vice President, Emerging Markets Research and Development (R&amp;D). During his time at GSK he led therapeutic product development activities in neurology, cardiovascular and metabolic diseases and served in senior business development roles. Dr. Macrae earned his B.Sc. in pharmacology
and his medical degree from Glasgow University, and a Ph.D. in molecular genomics at King&#39;s College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner.</p><p>&#34;Sangamo has successfully evolved from a platform company into a clinical-stage therapeutic product development organization based on our powerful zinc finger DNA-binding protein (ZFP) genome editing technology,&#34; said Mr. Lanphier. &#34;Sandy is the right person to take Sangamo forward into this next stage of our evolution as a company. He has a track record of building and growing organizations and his outstanding leadership and communication skills will be critical to the continued development of the company&#39;s therapeutic pipeline and current and future partnering activities.</p><p>&#34;I am extremely honored to be given the opportunity to take the helm at Sangamo &#8211; a company that
established the field of genome editing and leads the sector as an innovator in the development of novel human therapeutics based on this exciting technology. I look forward to building on the visionary work of Edward, one of the true pioneers and leaders in the gene and cell therapy industry,&#34; said Dr. Macrae. &#34;With multiple ZFP Therapeutics<sup>&#174;</sup> in clinical development, we have an exciting path forward as we focus on the clinical development and commercialization of one-time potentially curative therapies.&#34;</p><p>&#34;My commitment to Sangamo is unwavering, as is my passion for the company&#39;s people, technology and mission to bring one-time long lasting treatments to patients. I look forward to my continued involvement both in helping Sandy transition into his new role and as the chairman of the board of directors,&#34; concluded Mr.
Lanphier.</p><p>&#34;Over a year ago, as it became clear that Sangamo was moving from a platform company to a therapeutic product development company, the board discussed a leadership succession plan as the company entered this next phase of growth,&#34; said Mr. Ringo, the current chairman of the board. &#34;The board feels strongly that Sandy has the right skill set to advance the company&#39;s goals and we look forward to benefiting from his experience and leadership.&#34;</p><p>&#34;Edward has been a driving force behind the company and its vision and I look forward to continuing to collaborate with him as the new chairman of the board,&#34; continued Mr. Ringo.</p><p><b>About Alexander &#34;Sandy&#34; Macrae, M.B., Ch.B., Ph.D., MRCP
<br /></b>Dr. Macrae has nearly 20 years of experience in the pharmaceutical industry across a wide range of therapeutic areas in Europe, the United States and emerging markets. Since 2012, he has served as global medical officer of Takeda Pharmaceuticals, where he established and led the global medical office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at Glaxo SmithKline (GSK), where his last role was as senior vice president, emerging markets research and development (R&amp;D). In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK&#39;s global reach by providing R&amp;D strategies, clinical development and regulatory resources to enter emerging
markets and Asia-Pacific. Earlier in his career at GSK, he was vice president, business development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.</p><p>Dr. Macrae received his B.Sc. in pharmacology with first-class honors and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae earned his Ph.D. in molecular genomics at King&#39;s College, Cambridge, under the supervision of Nobel Prize-winner Sydney Brenner. He was a Wellcome Trust Advance Training Fellow at Hammersmith Hospital in London and a Howard Hughes Research
Associate at Duke University Medical Center in Durham, N.C., where he conducted post-doctoral research in molecular pharmacology under the guidance of Nobel Prize winner Robert Lefkowitz.</p><p><b>Conference Call
<br /></b>Sangamo will host a conference call today, June 1 at 8:30 a.m. ET, which also will be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under &#34;Events and Presentations&#34; http://investor.sangamo.com/events.cfm. A replay of the webcast will be available for two weeks after the call. </p><p>The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 24796846. A conference call replay will be available for one week following the conference call, from approximately 11:30 a.m. ET on June 1, 2016, to 11:30 a.m. ET on June 8, 2016. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively; ID number: 24796846.</p><p><b>About Sangamo
<br /></b>Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures<sup>&#174;</sup> for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company&#39;s proprietary In Vivo Protein Replacement Platform&#8482; (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B and MPS I, the first <i>in vivo</i> genome editing applications cleared by the FDA. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics<sup>&#174;</sup> for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell
disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington&#39;s disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company&#39;s website at www.sangamo.com.</p><p><i>ZFP Therapeutic<sup>&#174;</sup> is a registered trademark of Sangamo BioSciences, Inc.</i></p><p><i>This press release contains forward-looking statements regarding Sangamo&#39;s current expectations.  These forward looking statements include, without limitation, references to leadership transition, the research and development of ZFNs and ZFP TFs, clinical trials and therapeutic applications of Sangamo&#39;s ZFP technology platform. These statements are not guarantees of future performance and are subject to
certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo&#39;s operations and business environments. These risks and
uncertainties are described more fully in Sangamo&#39;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.</i></p><p><b><i>Important Additional Information Filed with the SEC </i></b></p><p><b><i>This press release may be deemed to be solicitation material in respect of the solicitation of proxies from stockholders in connection with Sangamo&#39;s 2016 annual meeting of stockholders (the &#34;Annual Meeting&#34;). Sangamo and its directors and certain executive officers are deemed participants in the solicitation of proxies from stockholders in connection with the Annual Meeting. On April 25, 2016, Sangamo filed a definitive proxy statement
relating to the Annual Meeting, and Sangamo has distributed the Notice of Internet Availability of Proxy Materials to its security holders. The definitive proxy statement will contain important information regarding the participants in the solicitation and proposals submitted to the stockholders for approval at the Annual Meeting, including the proposal to elect directors of Sangamo. </i></b></p><p><b><i>Stockholders of Sangamo are advised to read the definitive proxy statement prior to voting at the Annual Meeting. Stockholders of Sangamo may obtain, free of charge once they become available, copies of the definitive proxy statement and other documents filed by Sangamo with the SEC at the internet website maintained by the SEC at www.sec.gov. These documents may also be obtained free of charge by calling investor relations at Sangamo at (510) 970-6000.</i></b></p><p>Logo -
http://photos.prnewswire.com/prnh/20130102/SF35903LOGO </p><p> </p>
<br /><br /><p>CONTACT:  Sangamo BioSciences, Inc., Elizabeth Wolffe, Ph.D., (510) 970-6000, x271</p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sf35903logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sf35903logo.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" 0$" 0$! @(" @(" @(" 0(" @(" @(" @+_
MVP!# 0$! 0$! 0$! 0$" 0$! @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @+_P  1" !; 9 # 2(  A$! Q$!_\0
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M.T@[;R0%LD%?TB_X+17]G\0OV+?A3XZ\-746J>&[[XJ>!_%UAJ$ 9[>]\/\
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M,>!,ZX7\(O&["YBZ5#!X?B.ECLJY*D9SC&KC5!Q?*_<M&#M%*,KN[NM'^&\
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M7ABEWDG-N1@$'/\ .I_P3QNA\6O^"F-MXWL#(MIKGC+XT_$9;F,;?)TO6O\
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M+M%\."XMK1IO%GPM\$3>';B660>79W%]HFDL+>YDC^4(US&Q8_(^[ /[5_\
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M:VFQ_%K6;6(^$=,U/1I];M6\+P7GDR1RVMK=?Z/LVL#M;J17[[6,C)8VVX2
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M'>&?C;\:/%E[KLFB:#X_\2>*/%>LR^?=OI?AC5_$$DMU<W$QP%ATJP5$+$(
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M4EE"D?VGX@O;/3=2N ?XMU[XJE'&2?-SR 2/8_\ @N9XGOO%G[0GP/\ A?I
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MZ;_PDWDRV\<\5Q<:]XJO-)WR;\@K8OO (V[9-Q((JWX%^&__  5__8_TN_\
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MCGUBNM6U:0=L7V.H->%?\%[XXE^*/[.LX7$LO@;QZCL?[D.O^'D7..I+,/\
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M<ONVM[BO'_"[Z?.[\PA'E6C<9O[7--N/I>7O?.W8SXXMD)0K+MSQ'*ZY49)
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M42TY*+CS:=$FXV7:]V_T\C*,$#E3(DFX#Y)%,L?EE"2"C*V8SR>1C.<'BG)
M)-RR^85)8G$R-G))! 5<KCH.]:0AC!!" $ @')X!Z]Z7RTY&T#/7'&?RINF[
M1BG'DCLG33Y5VBW+3\=2>5R</:>^ELW*;E'R3NN;U:78J,BNNU5XSRC,Z <G
M[H!P!P0?4'!R,BGV\(C8D$DE2",18R2O0QQKCA0,#CCIGFK(10, <?4_XTH
D'3^M/D]Y23<?[MHN/R;CS+Y-%)2Y8J4N9QZV<;^MI-/YG__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
